Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
IGM Biosciences Inc (IGMS)
NASDAQ:IGMS
IGM Biosciences (IGMS) Stock Price & Analysis
270 Followers
IGMS Stock Chart & Stats
Day’s Range$9.09 - $9.67
52-Week Range― - ―
Previous Close$9.48
Volume190.57K
Average Volume (3M)N/A
Market Cap
$558.82M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 09, 2024EPS Estimate
-$0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$22.60Price Target Upside139.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
IGM Biosciences News
PremiumCompany Announcements
Igm Biosciences Is Worried About This – Should You Be Worried Too?
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentProgress in aplitabart clinical development and an understanding of DR5 as a target bolster confidence in the therapeutic's potential.
Market DynamicsCompany is observing favorable dynamics in the market uptake of Briumvi over Orevus, driven by faster infusion turnaround and better patient experience, which could lead to a significant market share gain.
Strategic FocusSNY's focus on IAI development aligns with their prioritization, indicating a strategic move rather than a negative reflection on the oncology programs.
Bears Say
Drug Development RisksRisks include: inability to achieve a best-in-class profile, failure to obtain approval for key drugs, setbacks with other candidates, and potential long-term dilution risk.
Financial MilestonesIGM is now eligible to receive up to $1.07B in milestones per target, a substantial decrease from the original $6B.
Partnership DevelopmentsSanofi drops oncology-focused portion of collaboration.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IGMS FAQ
What was IGM Biosciences Inc’s price range in the past 12 months?
Currently, no data Available
What is IGM Biosciences Inc’s market cap?
Currently, no data Available
When is IGM Biosciences Inc’s upcoming earnings report date?
IGM Biosciences Inc’s upcoming earnings report date is May 09, 2024 which is tomorrow.
How were IGM Biosciences Inc’s earnings last quarter?
IGM Biosciences Inc released its earnings results on Mar 07, 2024. The company reported -$1.01 earnings per share for the quarter, beating the consensus estimate of -$1.011 by <$0.001.
Is IGM Biosciences Inc overvalued?
According to Wall Street analysts IGM Biosciences Inc’s price is currently Undervalued.
Does IGM Biosciences Inc pay dividends?
IGM Biosciences Inc does not currently pay dividends.
What is IGM Biosciences Inc’s EPS estimate?
IGM Biosciences Inc’s EPS estimate is -$0.81.
How many shares outstanding does IGM Biosciences Inc have?
Currently, no data Available
What happened to IGM Biosciences Inc’s price movement after its last earnings report?
IGM Biosciences Inc reported an EPS of -$1.01 in its last earnings report, beating expectations of -$1.011. Following the earnings report the stock price went up 3.133%.
Which hedge fund is a major shareholder of IGM Biosciences Inc?
Among the largest hedge funds holding IGM Biosciences Inc’s share is Baker Bros Advisors LP. It holds IGM Biosciences Inc’s shares valued at 31M.
---
IGM Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.60 (139.66% Upside)
$22.60 (139.66% Upside)
Blogger Sentiment
Neutral
IGMS Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 451.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $278.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.62%
12-Months-Change
Fundamentals
Return on Equity
-100.48%
Trailing 12-Months
Asset Growth
-17.54%
Trailing 12-Months
Company Description
IGM Biosciences Inc
IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.
---
IGMS Earnings Call
Q4 2023
0:00 / 0:00
---
IGMS Stock 12 Months Forecast
Average Price Target
$22.60
▲(139.66% Upside)
Technical Analysis
Atara Biotherapeutics
―
Karyopharm Therapeutics
―
Kezar Life Sciences
―
Crispr Therapeutics AG
―
Best Analysts Covering IGMS
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
+30.48%
reiterated a buy rating 20 days ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +30.48% per trade.
---